Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review in SEDA Volume 40 summarizes new adverse reaction data for diuretics published in 2017, highlighting specific risks such as fractures with loop diuretics and hyperkalemia with spironolactone.

In this study, sandalore was found to activate OR2AT4, which inhibits senescent cell traits and restores proliferation in human keratinocytes, suggesting potential anti-aging applications.

In this open-label trial, 9-cis-retinoic acid showed moderate activity against Kaposi sarcoma in AIDS patients, but its use is limited by substantial side effects at higher doses.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.

This study enrolled nine patients to investigate the effects of oral psoralen and ultraviolet A therapy plus oral prednisolone for treating alopecia areata.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.

In this study, researchers found that azathioprine significantly improved hair regrowth in patients with moderate to severe alopecia areata over 10 years, with hair loss decreasing from 74.2% to 5.2% and demonstrating long-term safety and efficacy.

This study reported that a scalp serum containing Zanthoxylum ailanthoides extract effectively reduced inflammation and increased melanin production in cell assays, while demonstrating stable formulation and microbial safety, suggesting its potential to address scalp issues and enhance scalp health.

This study reports a rare case of alopecia areata on the scalp that was successfully treated with Sunetics Laser therapy, resulting in hair regrowth and repigmentation in areas of previous hair loss.

This study highlights that current research efforts to deliver anti-acne drugs to hair follicles have primarily targeted healthy follicles, overlooking the distinct characteristics of pathologically clogged follicles in acne vulgaris.

This study concluded that topical psoralen and ultraviolet A photochemotherapy is an effective and safe treatment for alopecia areata, as it produced a good response in 43.8% of patients.

This review found the strongest evidence supporting azelaic acid's use in treating rosacea, with somewhat less evidence for its effectiveness in melasma and acne vulgaris, and weaker support for its use in conditions like hidradenitis suppurativa and keratosis pilaris.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

In this survey of dermatologists, pimozide was most commonly identified as the preferred first-line antipsychotic for treating delusions of parasitosis, followed by risperidone.

In this study, sulfasalazine treatment resulted in cosmetically acceptable hair regrowth in 23% of patients with severe alopecia areata in whom a response could be determined.

This article reviews the potential of Acyzol, a zinc-containing drug, to treat and prevent zinc deficiency conditions, but it reports no new clinical findings.

This study found that phototoxic psoralen and ultraviolet A therapy with topical 8-MOP was effective in treating alopecia areata resistant to other treatments, improving hair regrowth with minimal side effects.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Most bald men don't protect their scalp from the sun, and doctors should encourage prevention.

This study found that azathioprine may improve relapses and disability in patients with neuromyelitis optica spectrum disorder but is associated with higher adverse events compared to mycophenolate mofetil.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.